- Home
- IRT vs ACAD Comparison
IRT vs ACAD Comparison
Compare IRT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRT
- ACAD
- Stock Information
- Founded
- IRT 2009
- ACAD 1993
- Country
- IRT United States
- ACAD United States
- Employees
- IRT N/A
- ACAD N/A
- Industry
- IRT Real Estate Investment Trusts
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- IRT Real Estate
- ACAD Health Care
- Exchange
- IRT Nasdaq
- ACAD Nasdaq
- Market Cap
- IRT 4.1B
- ACAD 3.8B
- IPO Year
- IRT 2013
- ACAD 2004
- Fundamental
- Price
- IRT $17.48
- ACAD $20.98
- Analyst Decision
- IRT Buy
- ACAD Buy
- Analyst Count
- IRT 10
- ACAD 18
- Target Price
- IRT $22.70
- ACAD $27.71
- AVG Volume (30 Days)
- IRT 2.9M
- ACAD 2.0M
- Earning Date
- IRT 07-30-2025
- ACAD 08-05-2025
- Dividend Yield
- IRT 3.65%
- ACAD N/A
- EPS Growth
- IRT N/A
- ACAD N/A
- EPS
- IRT 0.13
- ACAD 1.37
- Revenue
- IRT $641,330,000.00
- ACAD $996,283,000.00
- Revenue This Year
- IRT $5.23
- ACAD $13.39
- Revenue Next Year
- IRT $6.20
- ACAD $10.59
- P/E Ratio
- IRT $134.40
- ACAD $15.33
- Revenue Growth
- IRT N/A
- ACAD 22.42
- 52 Week Low
- IRT $17.10
- ACAD $13.40
- 52 Week High
- IRT $22.26
- ACAD $25.23
- Technical
- Relative Strength Index (RSI)
- IRT 39.35
- ACAD 45.70
- Support Level
- IRT $17.19
- ACAD $20.75
- Resistance Level
- IRT $17.74
- ACAD $23.09
- Average True Range (ATR)
- IRT 0.36
- ACAD 0.78
- MACD
- IRT 0.02
- ACAD -0.20
- Stochastic Oscillator
- IRT 42.76
- ACAD 9.83
About IRT Independence Realty Trust Inc.
Independence Realty Trust Inc is a real estate investment trust (REIT) that acquires, owns, operates, improves and manages multifamily apartment communities across non-gateway U.S. markets. It owns and operates multifamily apartment properties, across non-gateway U.S markets, including Louisville, Memphis, Atlanta, and Raleigh. The company is focused on gaining scale within key amenity-rich submarkets that offer school districts, retail, and various employment centers.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.